Shares of MacroGenics Inc. (NASDAQ:MGNX) have received a consensus rating of “Buy” from the ten brokerages that are presently covering the company. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $40.40.

A number of research firms have recently issued reports on MGNX. Wedbush restated an “outperform” rating and issued a $52.00 target price on shares of MacroGenics in a report on Thursday, November 3rd. Zacks Investment Research lowered MacroGenics from a “buy” rating to a “hold” rating in a report on Friday, November 4th. Cowen and Company began coverage on MacroGenics in a report on Wednesday, September 7th. They issued an “outperform” rating for the company. Citigroup Inc. lowered MacroGenics from a “buy” rating to a “neutral” rating and increased their target price for the company from $27.00 to $32.00 in a report on Thursday, August 4th. Finally, TheStreet lowered MacroGenics from a “hold” rating to a “sell” rating in a report on Tuesday, November 8th.

Shares of MacroGenics (NASDAQ:MGNX) opened at 29.69 on Tuesday. The stock’s market cap is $1.03 billion. MacroGenics has a 52-week low of $14.84 and a 52-week high of $36.11. The firm’s 50-day moving average price is $26.70 and its 200-day moving average price is $26.70.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by $0.17. MacroGenics had a negative net margin of 55.01% and a negative return on equity of 16.99%. The company had revenue of $3.30 million for the quarter, compared to analyst estimates of $12.45 million. During the same quarter last year, the company posted ($0.46) EPS. MacroGenics’s revenue was down 77.6% on a year-over-year basis. On average, equities research analysts forecast that MacroGenics will post ($1.50) earnings per share for the current fiscal year.

In other MacroGenics news, VP Lynn Cilinski sold 6,231 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $29.28, for a total transaction of $182,443.68. Following the transaction, the vice president now directly owns 8,154 shares of the company’s stock, valued at $238,749.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Jon Marc Wigginton sold 10,000 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $29.34, for a total transaction of $293,400.00. Following the transaction, the chief marketing officer now directly owns 10,000 shares in the company, valued at $293,400. The disclosure for this sale can be found here. Corporate insiders own 6.78% of the company’s stock.

A number of institutional investors have recently bought and sold shares of MGNX. FMR LLC increased its stake in shares of MacroGenics by 40.6% in the second quarter. FMR LLC now owns 4,977,997 shares of the biopharmaceutical company’s stock valued at $134,356,000 after buying an additional 1,438,175 shares in the last quarter. Point72 Asset Management L.P. increased its stake in shares of MacroGenics by 9.6% in the second quarter. Point72 Asset Management L.P. now owns 2,554,900 shares of the biopharmaceutical company’s stock valued at $68,957,000 after buying an additional 224,700 shares in the last quarter. BB Biotech AG increased its stake in shares of MacroGenics by 179.8% in the third quarter. BB Biotech AG now owns 1,455,000 shares of the biopharmaceutical company’s stock valued at $43,519,000 after buying an additional 935,000 shares in the last quarter. BlackRock Fund Advisors increased its stake in shares of MacroGenics by 5.5% in the third quarter. BlackRock Fund Advisors now owns 1,344,292 shares of the biopharmaceutical company’s stock valued at $40,208,000 after buying an additional 69,938 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of MacroGenics by 13.1% in the second quarter. Vanguard Group Inc. now owns 1,292,202 shares of the biopharmaceutical company’s stock valued at $34,876,000 after buying an additional 149,611 shares in the last quarter. 81.18% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

5 Day Chart for NASDAQ:MGNX

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.